Biologically Active Small Molecules

A dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 &microM restores the chemosensitivity of taxane-resistant cells to paclitaxel orally bioavailable, inhibiting FAK and augmenting

A dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 &microM restores the chemosensitivity of taxane-resistant cells to paclitaxel orally bioavailable, inhibiting FAK and augmenting

A synthetic, tridentate iron-selective chelator that dramatically reduces iron in the liver and blood, particularly during transfusional iron overload orally bioavailable, effectively reducing liver, serum, and cardiac iron concentration in

A synthetic, tridentate iron-selective chelator that dramatically reduces iron in the liver and blood, particularly during transfusional iron overload orally bioavailable, effectively reducing liver, serum, and cardiac iron concentration in

A synthetic, tridentate iron-selective chelator that dramatically reduces iron in the liver and blood, particularly during transfusional iron overload orally bioavailable, effectively reducing liver, serum, and cardiac iron concentration in

A synthetic, tridentate iron-selective chelator that dramatically reduces iron in the liver and blood, particularly during transfusional iron overload orally bioavailable, effectively reducing liver, serum, and cardiac iron concentration in

An orally bioavailable iron chelator that binds to iron in a 3:1 (ligand:iron) molar ratio.

An orally bioavailable iron chelator that binds to iron in a 3:1 (ligand:iron) molar ratio.

An orally bioavailable iron chelator that binds to iron in a 3:1 (ligand:iron) molar ratio.

The primary, active metabolite of aripiprazole.

The primary, active metabolite of aripiprazole.

The primary, active metabolite of aripiprazole.